Last reviewed · How we verify
SSGJ-705 combined with chemotherapy — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
SSGJ-705 combined with chemotherapy (SSGJ-705 combined with chemotherapy) — Shenyang Sunshine Pharmaceutical Co., LTD..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| SSGJ-705 combined with chemotherapy TARGET | SSGJ-705 combined with chemotherapy | Shenyang Sunshine Pharmaceutical Co., LTD. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- SSGJ-705 combined with chemotherapy CI watch — RSS
- SSGJ-705 combined with chemotherapy CI watch — Atom
- SSGJ-705 combined with chemotherapy CI watch — JSON
- SSGJ-705 combined with chemotherapy alone — RSS
Cite this brief
Drug Landscape (2026). SSGJ-705 combined with chemotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/ssgj-705-combined-with-chemotherapy. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab